New cancer therapies will demand better real-world data to understand long-term outcomes. This variant focuses on data infrastructure and measurement challenges over the next two decades.
open
Global / Unspecified, Global
WS02049
Cell and gene therapies may deliver durable remissions but have complex safety profiles. Post-marketing registries and patient-reported outcome platforms can close knowledge gaps.